Acute Myocardial Infarction

Part of the Contemporary Cardiology book series (CONCARD)


More than 1.1 million patients have an acute myocardial infarction (MI) in the United States (US) annually, and more than 50% of these patients die within the first hour, caused mainly by arrhythmias, particularly ventricular fibrillation (VF). Of those admitted to a hospital, approximately 15% die during hospitalization. In addition, more than 1 million patients with symptoms suggestive of acute MI are admitted annually to coronary care units (CCUs).


Acute Myocardial Infarction Thrombolytic Therapy Primary Percutaneous Coronary Intervention Right Bundle Branch Block Early Repolarization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson H, DANAMI-2. The Danish trial in acute coronary angioplasty in acute myocardial infarction. Clin Cardiol 2002;301:90–93.Google Scholar
  2. 2.
    Andersen HR, Nielsen TT, Vesterlund T, et al. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J 2003;146:234–241.PubMedCrossRefGoogle Scholar
  3. 3.
    Andersen HR, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. New Eng J Med 2003;349:733–742.PubMedCrossRefGoogle Scholar
  4. 4.
    Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Mangement of Patients With ST-Elevation Myocardial Infarction-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Management of Patients With STEMI: Executive Summary. J Am Coll Cardiol 2004;44:671–719.PubMedCrossRefGoogle Scholar
  5. 5.
    Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42:1879–1885.PubMedCrossRefGoogle Scholar
  6. 6.
    ASSENT—3: Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial of acute myocardial infarction. Lancet 2001;358:605–613.CrossRefGoogle Scholar
  7. 7.
    Blazing MA, de Lemos JA, White HD, et al. for the A to Z Investigators. Safety and efficacy of enoxaparin va unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. JAMA 2004;292:55–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Braunwald E. Application of current guidelines to the management of unstable angina and non-st-elevation myocardial infarction. Circulation 2003;108(Suppl I):III–37.Google Scholar
  9. 9.
    Califf RM, Bengtson JR. Current concepts: cardiogenic shock. N Engl J Med 1994;24:1724.CrossRefGoogle Scholar
  10. 10.
    Califf RM. Supplement on acute coronary syndromes: introduction. Circulation 2003;108:III–1.Google Scholar
  11. 11.
    Cannon CP, Braunwald E, McCabe CH. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [PROVE IT-TIMI 22 trial]. N Engl J Med 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  12. 12.
    CAPRICORN Investigators. The effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomized trial. Lancet 2001;357:1385–1390.CrossRefGoogle Scholar
  13. 13.
    CHARM: Granger CB, McMurray JJV, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM-alternative trial. Lancet 2003;362:772–776.PubMedCrossRefGoogle Scholar
  14. 14.
    COPERNICUS: carvedilol Prospective randomized cumulative survival study group effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.Google Scholar
  15. 15.
    Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003;41:7s–14s.PubMedCrossRefGoogle Scholar
  16. 16.
    CREDO Investigators: Steinhubl SE, Berger BP, Mann JT, et al. Esroy and sustsined dual oral antiplatelet therapy following PCI: a randomized controlled trial. JAMA 2002;288:2411.PubMedCrossRefGoogle Scholar
  17. 17.
    CURE: The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 2001;345:494–502.CrossRefGoogle Scholar
  18. 18.
    Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013–2020.PubMedGoogle Scholar
  19. 19.
    Fibrinolytic Therapy and Trialist (FIT) Cooperative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major mortality results from all randomized trials for more than 1000 patients. Lancet 1994:343:311.Google Scholar
  20. 20.
    Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, Valdecoxib, and cardiovascular risk. Circulation 2005;111:249.PubMedCrossRefGoogle Scholar
  21. 21.
    Grines CL. Clinical debate: primary angioplasty: the strategy of choice. N Engl J Med 1996;335:1313–1317.PubMedGoogle Scholar
  22. 22.
    Grines CL, Serruys P, O’Neill WW. Fibrinolytic Therapy: Is It A Treatment of the Past? Circulation 2003;107:2538–2542.PubMedCrossRefGoogle Scholar
  23. 23.
    Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993:328:673.PubMedCrossRefGoogle Scholar
  24. 24.
    Gruppo Italiano per lo Studio della Streptochinasi Nell ‘Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397.Google Scholar
  25. 25.
    GISSI-2: Gruppo Italiano per lo Studio della Sopravvivenza Nell ‘Infarto Miocardico. A factorial randomised trial of alteplase versus SK and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65.Google Scholar
  26. 26.
    GISSI-3: Gruppo Italiano per lo Studio della Soprawivenza nell’ Infarto Miocardico. effects of lisinopril and glyceryl trinitratesingly and together on 6-week mortality and ventricular function. Lancet 1994;343:1115.Google Scholar
  27. 27.
    GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673.CrossRefGoogle Scholar
  28. 28.
    GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, SK, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615.CrossRefGoogle Scholar
  29. 29.
    Hands ME, Cook EF, Stone PH, et al. Electrocardiographic diagnosis of myocardial infarction in the presence of complete left bundle branch block. Am Heart J 1988;16:23.CrossRefGoogle Scholar
  30. 30.
    HOPE; The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–153.CrossRefGoogle Scholar
  31. 31.
    Horan LG, Flowers NC, Tolleson WJ. The significance of diagnostic Q waves in the presence of bundle branch block. Chest 1970;58:214.PubMedGoogle Scholar
  32. 32.
    Hurst JW. Right ventricular infarction. N Engl J Med 1994;331:681.PubMedCrossRefGoogle Scholar
  33. 33.
    INJECT: International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with SK in acute myocardial infarction: trial to investigate equivalence. Lancet 1995;346:329.CrossRefGoogle Scholar
  34. 34.
    ISIS-2 (Second international study of infarct survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:350.Google Scholar
  35. 35.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:953.Google Scholar
  36. 36.
    ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomised factorial trial assessing early oral captorpil, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669.CrossRefGoogle Scholar
  37. 37.
    Jacobs AK. Primary angioplasty for acute myocardial infarction-Is it worth the wait? N Eng J Med 2003;349:798.CrossRefGoogle Scholar
  38. 38.
    Kastrati A, Mehilli J, Schlotterbeck K, et al. for BRAVE Investigators Late-Breaking Clinical Trial Abstracts. A randomized evaluation of early administration of reteplase plus abciximab or abciximab alone prior to percutaneous coronary intervention in patients with acute myocardial infarction. Circulation 2003;108:2723.Google Scholar
  39. 39.
    Keeley EC, Boura JA, Grines CL. Comparison of primary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Keeley EC, Grines CL. Primary coronary intervention for acute myocardial infarction. JAMA 2004;291:736–739.PubMedCrossRefGoogle Scholar
  41. 41.
    Kereiakes DJ. Adjunctive pharmacotherapy prior to percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: The role of modulating inflammation. Circulation 2003;108(Suppl I):III-22–III-27.Google Scholar
  42. 42.
    Khan M. Gabriel. Management of acute myocardial infarction. In: Cardiac Drug Therapy, sixth edition, WB Saunders, Philadelphia, 2003.Google Scholar
  43. 43.
    Khan M Gabriel. Beta blockers: the cornerstone of cardiac drug therapy. In: Cardiac Drug Therapy, sixth edition, WB Saunders, Philadelphia, 2003.Google Scholar
  44. 44.
    Khunti K, Samani NJ. Coronary heart disease in people of south-Asian origin. Important minority ethnic populations in many countries worldwide are people of south-Asian origin. Lancet 2004;364:2077.PubMedCrossRefGoogle Scholar
  45. 45.
    Kloner RA. The “Merry Christmas coronary” and “Happy New Year heart attack.” Phenomenon Circulation 2004;110:3744–3745.CrossRefGoogle Scholar
  46. 46.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670.PubMedCrossRefGoogle Scholar
  47. 47.
    Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004;350:277–280PubMedCrossRefGoogle Scholar
  48. 48.
    Lange RA, Hillis LD. Immediate angioplasty for acute myocardial infarction. N Engl J Med 1993;328:726.PubMedCrossRefGoogle Scholar
  49. 49.
    LATE Study Group. Late assessment of thrombolytic efficacy study with alteplase 6–24 hours after nset of acute myocardial infarction. Lancet 1993;342:759.CrossRefGoogle Scholar
  50. 50.
    Lau WC, Waskell LA, Watkins PB. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. Circulation 2003;107:32.PubMedCrossRefGoogle Scholar
  51. 51.
    Maehara A, Mintz GS, Bui AB, et al. The morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. J Am Coll Cardiol 2002;40:904–110.PubMedCrossRefGoogle Scholar
  52. 52.
    McMurray JJV, Pfeffer MA, Swedberg K, et al. Which inhibitor of the rennin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004;110:3281–3288.PubMedCrossRefGoogle Scholar
  53. 53.
    McSweeney JC, Cody M, O’Sullivan P, et al. Women’s early warning symptoms of acute myocardial infarction. Circulation 2003;108:2619–2623.PubMedCrossRefGoogle Scholar
  54. 54.
    Mehta RH, Granger CB, Alexander KP. Reperfusion strategies for acute myocardial infarction in the elderly. Benefits and risks. J Am Coll Cardiol 2005;45:471–478.PubMedCrossRefGoogle Scholar
  55. 55.
    Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–533.PubMedCrossRefGoogle Scholar
  56. 56.
    Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disablity from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard Univesity Press, 1996.Google Scholar
  57. 57.
    Reddy KS. Cardiovascular disease in non-western countries. N Engl J Med 2004;350:2438–2440.PubMedCrossRefGoogle Scholar
  58. 58.
    Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation 2005;111:250–253.PubMedCrossRefGoogle Scholar
  59. 59.
    Saia F, Lemos PA, Chi-Hang Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction. Circulation 2003;108:1927.PubMedCrossRefGoogle Scholar
  60. 60.
    Salukhe TV, Henein MY, Sutton R. Ischemic mitral regurgitation and its related risk after myocardial infarction. Circulation 2005;111:254–256.PubMedCrossRefGoogle Scholar
  61. 61.
    Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003;41:15s–22sPubMedCrossRefGoogle Scholar
  62. 62.
    TAXUS: Stone GW, Ellis SG, Cox DA, et al. for TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Eng J Med 2004;350:221–231.CrossRefGoogle Scholar
  63. 63.
    Terrin ML, Williams DO, Kleiman NS, et al. Two-and three-year results of the thrombolysis in myocardial infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1993;22:1763.PubMedCrossRefGoogle Scholar
  64. 64.
    TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618.CrossRefGoogle Scholar
  65. 65.
    TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable anginaand non-Q wave myocardial infarction: results of the TIMIIIIB Trial. Circulation 1994;89:1545.Google Scholar
  66. 66.
    Topol EJ. Current Status and Future Prospects for Acute Myocardial Infarction Therapy. Circulation 2003;108(Suppl I):III-6–III-13.Google Scholar
  67. 67.
    Topol B J, Califf RM, Lee KL, on behalf of the GUSTO Investigators. More on the GUSTO trial. N Engl J Med 1994;31:277.CrossRefGoogle Scholar
  68. 68.
    Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic heart disease: a call for specialized centers. Circulation 2003;107:1463–1466.PubMedCrossRefGoogle Scholar
  69. 69.
    Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002;105:393–343.CrossRefGoogle Scholar
  70. 70.
    Yamaji H, Iwsaki K, Kusachi S, et al. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography; ST-segment elevation in AVR with less ST-segment elevation in lead V1. J AM Coll Cardiol 2001;38:1348.PubMedCrossRefGoogle Scholar
  71. 71.
    Yusuf S, Hawken S, Ounpuu S, et al. on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–952.PubMedCrossRefGoogle Scholar
  72. 72.
    Wang K, Asinger RW, Marriott HJL. ST elevation in conditions other than acute myocardial infarction. N Engl J Med 2003;349:2128–2135.PubMedCrossRefGoogle Scholar
  73. 73.
    Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003;289:331–342.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations